Ignite Creation Date:
2025-12-24 @ 3:35 PM
Ignite Modification Date:
2025-12-28 @ 8:34 AM
Study NCT ID:
NCT01564992
Status:
UNKNOWN
Last Update Posted:
2018-08-13
First Post:
2012-02-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Drug Interaction With Genes in Parkinson's Disease
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Study Overview
Official Title:
Drug Interaction With Genes in Parkinson's Disease
Status:
UNKNOWN
Status Verified Date:
2018-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DIGPD
Brief Summary:
This observational study aims at identifying gene modifiers of Parkinson Disease (PD) and of treatment response and adverse events of antiparkinsonian drugs. Six hundred PD patients will be followed annually for up to 5 years. A biological collection will be associated with a full clinical assessment of motor and non motor symptoms, medical and treatment history, environmental factors. The association between candidate gene polymorphisms and disease or treatment complications will be analyzed.
Detailed Description:
Title : Drug interaction with genes in Parkinson Disease
Objective:
To identify genes associated to disease and treatment complication and response.
Number of subjects: 500
Study duration : 6 years
Design:
Prospective cohort with biological collection
Primary objective:
Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
Secondary objectives:
* Prevalence and incidence of disease or treatment complications
* Clinical risk factor for disease or treatment complications
* Biomarkers of disease progression, disease or treatment complications
Objective:
To identify genes associated to disease and treatment complication and response.
Number of subjects: 500
Study duration : 6 years
Design:
Prospective cohort with biological collection
Primary objective:
Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
Secondary objectives:
* Prevalence and incidence of disease or treatment complications
* Clinical risk factor for disease or treatment complications
* Biomarkers of disease progression, disease or treatment complications
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: